Project Grant R21CA303374
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $402K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Honolulu, HI 96813, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded the University of Hawaii at Manoa a $402,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for research investigating neutrophilic myeloid-derived suppressor cells (PMN-MDSCs) as an immunotherapy target in hepatoblastoma. The grant, effective from May 15, 2025 through April 30, 2027, will deliver preclinical research combining innovative mouse genetic approaches with therapeutic studies to determine how...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. This award supports exploratory research into the role of antisense ribonucleic acids (asRNAs) in melanoma development and transformation. The project will deliver scientific research and analysis focused on...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $419,036 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded on September 10, 2025, with completion targeted for March 9, 2028. This award funds research and training activities focused on investigating sex hormone signaling in hepatocellular carcinoma (HCC), specifically examining the role of androgen receptor (AR) signaling as a...
- Federal Project Grant Award Summary The University of Pennsylvania received a $667,041 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through February 28, 2031. This five-year research initiative focuses on the validation and credentialing of patient-derived xenograft (PDX) models of hepatocellular carcinoma (HCC) using patient-level clinical data. The project addresses a critical gap in preclinical...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute awarded a $167,500 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Massachusetts Medical School, effective May 1, 2026 through April 30, 2028. This award supports the development and application of HARP-SEQ (a novel, highly sensitive sequencing method) to map 3-methylcytidine (M3C) RNA modifications in messenger RNA at single-nucleotide resolution. The project integrates advanced chemical...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The University of North Carolina at Chapel Hill received a $399,829 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period May 15, 2026 through April 30, 2028. This award supports the development of a population-based hepatocellular carcinoma (HCC) surveillance registry to improve early detection and risk stratification among patients with cirrhosis and metabolic dysfunction-associated...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $687,593 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective May 12, 2026, with completion targeted for April 30, 2031. The award funds fundamental research investigating cysteine acquisition and utilization mechanisms in lung adenocarcinoma. The project delivers scientific research services aimed at understanding how...